Investigation of Subclinical Markers of Multiple Sclerosis

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type. The objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting MS patients, and in patients with relapsing-remitting MS treated with immunomodulation. The results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting MS.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
View:

• Subjects with a documented diagnosis of relapsing-remitting MS according to the Mc Donald criteria (2005) and with EDSS achievement of 0-3.5 according to the modified Kurtzke's EDSS (Expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis

Locations
Other Locations
Croatia
University of Split School of Medicine
RECRUITING
Split
Contact Information
Primary
Maja Rogić Vidaković, MSc, PhD
maja.rogic@mefst.hr
0038598508210
Backup
Sanda Pavelin, MD, PhD
spavelin@gmail.com
Time Frame
Start Date: 2020-11-23
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 50
Treatments
Relapsing-remmitting MS group treated with corticosteroids
1. Clinical testing~2. Neurophysiological examination (TMS, EMNG)~3. Psychomotor examination~4. Neuropsychological evaluation~5. Flow cytometry~6. ELISA
Relapsing-remmitting MS group treated with immunomodulation
1\. Clinical testing 2. Neurophysiological examination (TMS, EMNG) 4. Neuropsychological evaluation 5. Flow cytometry
Healthy control group
5\. Flow cytometry
Authors
Linda Lušić Kalcina
Sponsors
Collaborators: University Hospital of Split
Leads: University of Split, School of Medicine

This content was sourced from clinicaltrials.gov

Similar Clinical Trials